Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

FOPO nets antibody developer Xoma $53.9mm

Executive Summary

Less than four months after completing a $30mm follow-on public offering, Xoma Corp. (monoclonal antibodies for diabetes, cancer, and other diseases) is again turning to the financing vehicle, netting $53.9mm by selling 10.9mm shares (including the overallotment) for $5.25. The biotech plans to spend the proceeds on lead candidate gevokizumab, in Phase III for non-infectious uveits (partnered with Servier in 2011), and the preclinical XMet program of insulin activators and sensitizers.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies